Printer Friendly

PHS TASK FORCE RECOMMENDS PROPHYLAXIS AGAINST AIDS-RELATED INFECTION WITH MYCOBUTIN

 DUBLIN, Ohio, July 23 /PRNewswire/ -- A U.S. Public Health Service (PHS) Task Force announced today guidelines for the use of MYCOBUTIN(R) (rifabutin capsules) as prophylaxis (prevention) against Mycobacterium avium complex (MAC). MAC, a life-threatening bacterial opportunistic infection, is a major cause of illness and death in people with AIDS (PWAs). MYCOBUTIN was developed by Adria Laboratories, Columbus, Ohio.
 The task force report, "Recommendations on Prophylaxis and Therapy for Disseminated Mycobacterium avium complex for Adults and Adolescents Infected with Human Immunodeficiency Virus" was in a supplement to Morbidity and Mortality Weekly Report published by the Centers for Disease Control & Prevention (CDCP). The task force recommends that patients with HIV infection and CD4 counts below 100 be administered 300 mg of MYCOBUTIN daily as prophylaxis against MAC. Prophylaxis with MYCOBUTIN is recommended for the patient's lifetime. However, if a patient develops disseminated MAC (where the infection is scattered throughout the body) while on MYCOBUTIN, multiple drug therapy is recommended. Patients should be examined prior to prophylaxis to ensure that they do not have active diseases due to MAC, M. tuberculosis or any other mycobacterial species.
 "Prophylaxis against MAC, as with other AIDS-related opportunistic infections, offers real benefits to people with AIDS," says Fred Gordin, M.D., chief, infectious diseases, Veterans Affairs Medical Center. "By preventing the onset of this debilitating infection, effective prophylaxis can positively impact the life of the patient with advanced HIV disease."
 For the treatment of MAC, the task force recommends a lifetime multiple drug treatment, even though the identification of the best combination and dosage for MAC treatment is the aim of several trials just about to start. The diagnosis, prophylaxis and therapy for HIV infected children should follow recommendations similar those for adolescents and adults.
 MAC affects 50 percent of PWAs within 2-1/2 years after AIDS has been diagnosed, making it the most common AIDS-related bacterial infection. In addition to drastic weight loss, MAC symptoms include severe diarrhea, fever, night sweats, abdominal pain, chills, fatigue, anemia and abnormal liver tests.
 Mycobutin was approved for marketing by the Food and Drug Administration in December 1992 for the prevention of disseminated Mycobacterium avium complex disease in patients with advanced HIV infection.
 Adria Laboratories is a recognized leader in oncology drug research and development. MYCOBUTIN is marketed through a co-promotional agreement between Adria and SmithKline Beecham.
 -0- 7/23/93
 /CONTACT: Karin Leuffgen of Porter/Novelli, 212-315-8231, for Adria Laboratories/


CO: Adria Laboratories ST: Ohio IN: MTC SU:

LG-TS -- NY017 -- 5028 07/23/93 09:22 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 23, 1993
Words:420
Previous Article:MEDCO RESEARCH REACHES ADENOSCAN MANUFACTURING AGREEMENT WITH ABBOTT LABORATORIES
Next Article:SUNBEAM-OSTER ANNOUNCES REPURCHASE OF 12.4 MILLION SHARES AND LITIGATION SETTLEMENT
Topics:


Related Articles
ADRIA LABORATORIES REPRESENTATIVES AVAILABLE FOR COMMENT
FDA ADVISORY COMMITTEE RECOMMENDS APPROVAL OF MYCOBUTIN(TM) FOR THE PREVENTION OF AIDS-RELATED INFECTION
FDA APPROVES RIFABUTIN FOR PREVENTION OF MAC DISEASE
ADRIA LABORATORIES AND SMITHKLINE BEECHAM AGREE TO CO-PROMOTE MYCOBUTIN
ADRIA ANNOUNCES FINALIZATION OF MYCOBUTIN CO-PROMOTION AGREEMENT
FEDERAL TASK FORCE ANNOUNCES PREVENTION AND TREATMENT RECOMMENDATIONS FOR AIDS-RELATED INFECTION
PHARMACIA INC. ANNOUNCES CLINICAL TRIALS FOR TUBERCULOSIS PREVENTION; STUDY TO TARGET PEOPLE WITH HIV AND THE UNDERSERVED
NEW DATA CONFIRM BENEFIT OF CMV PROPHYLAXIS WITH CYTOVENE
New Data Published in New England Journal of Medicine Suggest Clarithromycin is Effective in Prolonging Life of Aids Patients
Pharmacia & Upjohn and Gilead Sciences Receive European Recommendation for Vistide

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters